Vertex CEO Jeffrey Leiden reportedly sent a biting letter to Prime Minister Theresa May as the battle with the National Institute for Health and Clinical Excellence over the price of Orkambi continues.
In it, according to a Fierce Pharma report, Leiden says the rejection of Vertex’s pricing offer for Orkambi, a cystic fibrosis treatment, could present significant problems for the U.K.’s biopharma ecosystem.
Leiden took a threatening tone in the letter, according to the report, after saying the company was second-guessing its commitment in the U.K. England currently is home to two Vertex operations, including an international headquarters in London and a research and development center around Oxford.
The National Health Service (NHS) after negotiations broke down last week said the drugmaker should adopt a new strategy if it truly stands behind its proposed price.
“If Vertex really believe they are offering a reasonable deal, they should waive their confidentiality clause and let patients and taxpayers judge whether it is fair,” the agency said.